Parsaclisib: all 31 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCLNot yet recruitingNCT05238064Phase 1/2
• IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingNCT05073250Phase 2
• Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaTerminatedNCT05073458Phase 3Results posted
• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)TerminatedNCT04809467Phase 1/2Results posted
• To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingNCT04661007Phase 1/2Results posted
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedNCT04551066Phase 3Results posted
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedNCT04551053Phase 3Results posted
• Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)CompletedNCT04434937Phase 2Results posted
• A Study of INCB050465 in Primary Sjögren's SyndromeCompletedNCT03627065Phase 2Results posted
• A Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaCompletedNCT03538041Phase 2Results posted
• A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorCompletedNCT03235544Phase 2Results posted
• A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)CompletedNCT03144674Phase 2Results posted
• A Study of INCB050465 in Relapsed or Refractory Follicular LymphomaCompletedNCT03126019Phase 2Results posted
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)CompletedNCT02998476Phase 2Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT05083208Phase 1
• A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT04849715Phase 3
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.CompletedNCT04831996Phase 1
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.CompletedNCT04831944Phase 1
• To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)WithdrawnNCT04796922Phase 3
• Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedNCT04774068Phase 1
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
• IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone LymphomaCompletedNCT04298879Phase 2
• Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast CancerWithdrawnNCT04142554Phase 1
• A Study of the Safety and Tolerability of INCB050465 in Pemphigus VulgarisWithdrawnNCT03780166Phase 2
• A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaCompletedNCT03688152Phase 1
• INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCompletedNCT03589651Phase 1
• A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)CompletedNCT03314922Phase 1
• Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedNCT03039114Phase 1
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
• Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsTerminatedNCT02559492Phase 1

← Parsaclisib overview